Dapansutrile is an orally active, specific and potent inhibitor of NLRP3 inflammasome activation that decreases IL-1β and IL-18 release. Dapansutrile exhibits no effect on NLRC4 and AIM2 inflammasomes activation. It appears that Dapansutrile directly interact with NLRP3. It does not show hematological, or organ toxicities in humans at oral doses up to 1,000 mg/day
orally active, specific and potent inhibitor of NLRP3 inflammasome activation; anti-inflammatory
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse
Journal of Cardiovascular Pharmacology, 73(4), 215-222 (2019)
OLT1177, a ?-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
Proceedings of the National Academy of Sciences of the USA, 115(7), E1530-E1539 (2018)
NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis
Arthritis Research & Therapy, 20(1), 169-169 (2018)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.